Skip to content

Medical emergency? What to do

Drug Can Reduce Risk of Death, Heart Attack, and Stroke in Diabetes Patients

3-RXPublished October 11, 20052 min read

Key points

  • A Diabetes drug called pioglitazone can reduce the risk of death, heart attack, and stroke in high-risk patients with type 2 diabetes, concludes an article in this week’s issue of The Lancet.
  • John Dormandy (St George’s Hospital, London, UK) and colleagues recruited 5238patients with type 2 diabetes who had evidence of macrovascular disease from centres in 19 European countries.
  • In an accompanying Comment Hannele Yki-Jarvinen (University of Helsinki, Finland) states: “Overall, PROactive is an important study that leaves us with some good news, some bad news, and some unknowns.
  • Patients with diabetes have a two to four-fold increased risk of a cardiovascular event compared with non-diabetics.

A Diabetes drug called pioglitazone can reduce the risk of death, heart attack, and stroke in high-risk patients with type 2 diabetes, concludes an article in this week’s issue of The Lancet.

Patients with diabetes have a two to four-fold increased risk of a cardiovascular event compared with non-diabetics. Until now there has only been indirect evidence suggesting that pioglitazone could reduce cardiovascular-related deaths and illness in diabetics.

John Dormandy (St George’s Hospital, London, UK) and colleagues recruited 5238patients with type 2 diabetes who had evidence of macrovascular disease from centres in 19 European countries. Participants were randomly assigned either pioglitazone (2605) or placebo (2633) in addition to their existing medication(s) for diabetes and cardiovascular disease. Patients were followed-up for an average of 34·5 months. The investigators found that for a combined endpoint of death, heart attack, stroke, acute coronary syndrome, and cardiac or leg interventions the treatment group had 803 events while the placebo group had 900events. There were fewer adverse events in the treatment group, although there was an increase in reported heart failure, however, the number of deaths from heart failure were similar in each group. The researchers also found that patients receiving pioglitazone did not need to start taking insulin as soon as those assigned the placebo. The results indicate that giving 1000patients pioglitazone would avoid 21 first heart attacks, strokes, or deaths over 3years.

Professor Dormandy states: “. . . in patients with type 2 diabetes who are at high cardiovascular risk, pioglitazone improves cardiovascular outcome, and reduces the need to add insulin to glucose lowering-regimens compared with placebo . . . We believe our results are generalisable to all patients with type 2 diabetes.”

In an accompanying Comment Hannele Yki-Jarvinen (University of Helsinki, Finland) states: “Overall, PROactive is an important study that leaves us with some good news, some bad news, and some unknowns. The clinician, of course wants to know who should be treated with pioglitazone. Unfortunately, the study does not provide such answers. It showed that pioglitazone is beneficial in patients with type 2 diabetes and pre-existing macrovascular disease who do not develop heart failure.”

Source: The Lancet

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.